TenNor Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TenNor Therapeutics Ltd.
Gene Therapy, RNA-Focused Biotechs Lead China December Fundraising
Venture capital and private equity firms pumped a combined $102m into seven Chinese biotechs in major deals announced during December.
Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Biopharma Quarterly Dealmaking Statistics, Q3 2016
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
- Contract Research, Toxicology Testing-CRO
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.